Franklin Lakes, NJ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced that a new study, "Universal Surveillance for Methicillin-Resistant Staphylococcus aureus in 3 Affiliated Hospitals," published in Annals of Internal Medicine,demonstrates that universal surveillance of all hospital admissions for methicillin-resistant Staphylococcus aureus (MRSA) using the BD GeneOhm™ MRSA real-time polymerase chain reaction (PCR) diagnostic test can significantly reduce MRSA infection rates.
Led by researchers at Evanston Northwestern Healthcare (ENH) in Evanston, Illinois, the study is the first and largest in the United States to show the impact of implementing a universal, active surveillance program coupled with a comprehensive infection prevention program to reduce MRSA infections. MRSA bacteria can cause a potentially fatal infection that does not respond to common antibiotics and is a significant cause of hospital-associated infections.
Study authors report ENH reduced MRSA infection rates by 70 percent in less than two years. The reductions were significant in every category measured, such as surgical site, bloodstream, urinary tract and respiratory infections. Furthermore, this study indicates that limited active surveillance conducted only in the intensive care units did not produce the desired result, and that MRSA infections were significantly reduced only when universal all admissions testing was performed.
"BD is fully committed to the prevention of MRSA infections using active surveillance screening as a core component of a comprehensive infection prevention program," said Tobi Karchmer, MD, MS, Medical Affairs Director, BD Diagnostics - GeneOhm. "Each institution needs to perform its own risk assessment and determine the best approach to implementing an MRSA infection prevention program. In some institutions, universal active surveillance may be appropriate, as demonstrated in this new study, and in others it may be more appropriate to focus on certain high-risk patient populations."
About the BD GeneOhm MRSA Assay
The BD GeneOhm MRSA assay is a qualitative in vitro molecular diagnostic test cleared by the U.S. Food & Drug Administration for the direct detection of MRSA nasal colonization. Since its launch, over 2 million patients have been tested with the BD GeneOhm assay in over 250 healthcare institutions worldwide that are committed to reducing MRSA infections and improving patient outcomes.
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.